By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Under an agreement announced on Monday, Wavi will apply its bioinformatics expertise to SomaLogic's proprietary proteomics assays.

Additionally, the two companies will plan two clinical studies in dementia that combines Wavi's electroencephalogram-based biomarkers and SomaLogic's blood-based protein biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.